Anti-PM/Scl-75 and Tendinopathy: Evaluation Strategy
Anti-PM/Scl-75 antibodies are not typically associated with tendinopathy as a primary manifestation; however, your patient's serologic and inflammatory profile warrants systematic evaluation for an underlying connective tissue disorder that could contribute to musculoskeletal symptoms through muscle, joint, or systemic inflammatory mechanisms.
Understanding the Anti-PM/Scl-75 Clinical Phenotype
Anti-PM/Scl antibodies define a specific subset of systemic sclerosis (SSc) and overlap syndromes with characteristic features that do not include tendinopathy as a recognized manifestation:
Primary manifestations include myositis/myalgia (51% vs 14% in antibody-negative patients), interstitial lung disease (ILD occurs in 86.7% of anti-PM/Scl-positive patients), hand joint contractures, calcinosis, and cutaneous dermatomyositis features 1, 2, 3.
Musculoskeletal involvement centers on muscle inflammation and joint contractures rather than tendon pathology—anti-PM/Scl-75 specifically correlates with younger age, more active disease, and joint contractures 4.
The antibody can disappear over time (seroreversion), but the clinical syndrome may persist; one positive test historically is clinically relevant even if subsequent testing is negative 5.
Direct Answer to Tendinopathy Question
Tendinopathy is not a recognized feature of anti-PM/Scl-associated disease. Your patient's tendinopathy more likely represents:
- A separate mechanical or degenerative process
- Manifestation of joint contractures causing altered biomechanics
- Periarticular inflammation mimicking tendinopathy clinically
The elevated inflammatory markers (ESR/CRP) and thrombocytosis you describe are consistent with active SSc, particularly early diffuse disease with progressive ILD 5. Thrombocytosis specifically serves as a potential predictor of lung fibrosis 5.
Mandatory Evaluation Steps
Immediate Pulmonary Screening (Highest Priority)
Anti-PM/Scl antibodies are listed as a specific risk factor for ILD development in the 2023 ACR/CHEST guidelines 6:
- High-resolution chest CT is essential—ILD affects 86.7% of anti-PM/Scl-positive patients and may be the sole manifestation in 26.7% 3.
- Pulmonary function tests (spirometry with DLCO) to establish baseline and detect restrictive physiology 6.
- Most anti-PM/Scl ILD presents as non-specific interstitial pneumonia (58%) with mild-to-moderate severity, and importantly shows good functional outcome compared to other SSc-ILD 1, 3.
Muscle Disease Assessment
Given the 51% prevalence of skeletal muscle involvement in anti-PM/Scl-positive SSc 7:
- Creatine kinase (CK) level—elevation associates particularly with anti-PM/Scl-100, though your patient had anti-PM/Scl-75 4.
- Aldolase if CK is normal but myositis is suspected clinically.
- MRI of proximal muscles if weakness, myalgia, or elevated enzymes are present to detect inflammatory myopathy.
- Consider electromyography if muscle involvement remains unclear after non-invasive testing.
Systemic Sclerosis Confirmation
Even without overt skin thickening, SSc can be diagnosed by the combination of Raynaud phenomenon, SSc-specific autoantibodies, and/or nailfold capillaroscopy changes 5:
- Nailfold capillaroscopy to identify scleroderma pattern (dilated capillaries, hemorrhages, avascular areas) 5, 8.
- ANA with pattern (nucleolar pattern strongly associates with anti-PM/Scl: 87% vs 32% in antibody-negative patients) 7.
- Complete SSc antibody panel if not already done: anti-Scl-70, anti-centromere, anti-RNA polymerase III, anti-U1 RNP, anti-Ku 5.
Renal Surveillance
Although scleroderma renal crisis is not typically part of the anti-PM/Scl syndrome 1, one case report documents its occurrence 8:
- Serial blood pressure monitoring (home measurements).
- Serum creatinine and urinalysis at baseline and periodically 5.
- Your patient's chronic borderline anemia and reduced reflexes could reflect uremic neuropathy if renal function is declining.
Address Nutritional Deficiencies
- Correct vitamin D deficiency (target 25-OH vitamin D >30 ng/mL).
- Treat iron deficiency with oral or IV iron depending on severity and tolerance.
- These deficiencies can contribute to myalgia, weakness, and fatigue that may be misattributed to connective tissue disease.
Neurologic Evaluation for Reduced Reflexes
Reduced reflexes are not a feature of anti-PM/Scl disease:
- Thyroid function tests (TSH, free T4)—hypothyroidism is common in autoimmune disease and causes hyporeflexia 5.
- Vitamin B12 and folate levels.
- Nerve conduction studies if peripheral neuropathy is suspected clinically.
- Consider cervical spine imaging if radiculopathy could explain reflex changes.
Common Pitfalls to Avoid
Do not dismiss the prior positive anti-PM/Scl-75 simply because repeat testing is negative—seroreversion occurs but does not negate the clinical significance of prior positivity 5.
Do not attribute tendinopathy to anti-PM/Scl disease—this diverts attention from the true high-risk manifestations (ILD, myositis) and delays appropriate screening 1, 3.
Do not overlook ILD screening—it is the dominant feature in this antibody subset and may be asymptomatic early; thrombocytosis and elevated acute-phase reactants in your patient are red flags for progressive lung disease 5, 3.
Do not assume limited skin involvement means limited disease—anti-PM/Scl patients often have limited cutaneous SSc (72%) but still develop significant internal organ involvement 7.
Prognosis Context
Anti-PM/Scl-positive SSc patients have significantly better 10-year survival (91% vs 65%, HR 0.32) compared to antibody-negative patients, and their ILD typically has better functional outcome 1, 7. However, 16.7% experience disease relapse, necessitating ongoing monitoring 3.